Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Written informed consent
2. Histologically confirmed B-cell lymphoma of the following subtypes:
* LBCDL
* Grade 3b follicular lymphoma
* Mantle-cell lymphoma
* Transformed B-cell lymphoma
You may not be if
3. High-risk B-cell CD20+ lymphoma defined by
* Having attained less than PR after two chemotherapy lines
* Post-transplantation relapse
* Presence of disease detected through a metabolic approach (PET/CT or else CT+PET) either before or after autologous transplantation
* Inability to collect enough stem cells for autologous transplantation
4. Stable disease at the time of transplantation
5. Age between 18 and 65
6. Performance status (ECOG) ≤ 2
7. Normal and suitable pulmonary function (DLCO ≥ 30%)
8. Left ventricular ejection fraction (LVEF) determined by ventriculography or echocardiogram ≥ 40%
9. Normal hepatic and renal function, with creatinine ≤ 2 mg/dl and Bi ≤ 1.5 mg/dl, and alkaline phosphatase ≤ 2.5 x UNL ; AST, ALT ≤ 2.5 x UNL (≤ 5 x UNL if hepatic infiltration)
1. Prior treatment with radiopharmaceutical agents
2. HIV-associated lymphoma
3. Presence of human anti-mouse antibodies (HAMA) or anti-chimeric antibodies (HACA)
4. Patient's inability to follow the protocol
5. Hypersensitivity to 90Y-itritumomab tiuxetan
6. Presence of severe pathologies that preclude chemotherapeutic treatment
7. Pregnant women or pregnancy risk due to inappropriate contraceptive measures
8. Breastfeeding women
Clareo Health | Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL)
